Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes

Diabetes Care

Volumn 28, Issue 2, 2005, Pages 266-272

  Ceriello, Antonio ^a   Johns, Don ^b   Widel, Mario ^b   Eckland, David J ^c   Gilmore, Kathryn J ^b   Tan, Meng H ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b ELI LILLY AND COMPANY   (United States)

^c Takeda Europe R and D Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC LOAD; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 12844274252     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.2.266     Document Type: Article

References (38)

1. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Int Med 131:281-303, 1999
2. Gurnell M, Savage DB, Chatterjee V, Krishna K, O'Rahilly S: Peroxisome proliferator-activated receptor [gamma] and its therapeutic modulation. J Clin Endocrinol Metab 88:2412-2421, 2003
3. Stumvoll M: Thiazolidinediones: some recent developments. Exp Opin Invest Drugs 12:1179-1187, 2003
4. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahanlaki S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719, 2001
5. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 3:E214-E223, 1979
6. Radziuk J: Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endomnol Metab 85:4426-4429, 2000
7. Wallace, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495, 2004
8. Levy JC, Matthews DR, Hermans MP: Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192, 1998
9. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-2410, 2000
10. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470, 1999
11. Miyazaki Y, Matsuda M, DeFronzo RA: Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25:517-522, 2002
12. Kuo CS, Hwu CM, Kwok CF, Hsiao LC, Weih MJ, Lee SH, Lee YS, Ho LT: Surrogate estimates of insulin sensitivity in Chinese diabetic patients and their offspring. Diabet Med 19:735-740, 2002
13. Herz M, Johns D, Reviriego J, Grossman L, Godin C, Duran S, Hawkins F, Lochnan H, Jimenez FE, Hardin PA, Konkoy CS, Tan MH: A randomised, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia: oral antihyperglycemic medications-naive patients with type 2 diabetes mellitus. Clin Ther 4:1074-1095, 2003
14. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S, Shestakova M, Herz M, Johns D, Schluchter BJ, Festa A, Tan MH: Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrin Metab 88:1637-1645, 2003
15. Tan M: Johns D, Strand J, Halse J Madsbad S, Eriksson J, Clausen J, Konkoy C, Herz M: the GLAC Study Group: Sustained effects of pioglitazone vs glibenclamide on insulin sensitivity, glycemic control, and lipid profiles in patients with T2D. Diabet Med 21:859-866, 2004
16. 1c interrelationship in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 24:2023-2029, 2001
17. 1c in the Diabetes Control and Complications Trial. Diabetes Care 25:275-278, 2002
18. 1c. Diabetes Care 26:881-885, 2003
19. Ceriello A: Impaired glucose tolerance and cardiovascular disease: the possible role of postprandial hyperglycemia. Am Heart J 147:803-807, 2004
20. Ceriello A: The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 46 (Suppl. 1):M9-M16, 2003
21. American Diabetes Association: Postprandial blood glucose (Consensus Statement). Diabetes Care 24:775-778, 2001
22. Canadian Diabetes Association: Canadian Diabetes Association Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: targets for glycemic control. Canadian J Diabetes 27 (Suppl. 2):S18-S20, 2003
23. European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med 16:716-730, 1999
24. American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self Management: 2002 update. Endocr Pract 8 (Suppl. 1):40-77, 2002
25. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. Ann Int Med 128:176-185, 1998
26. Edwards GC, Lee CEF, Maher J, Urquhart R: The effects of pioglitazone, metformin and gliclazide as monotherapy or in combination on 3-hour OGTT investigations (Abstract). Diabetologia 46 (Suppl. 2):A288, 2003
27. Charbonnel BH, Matthews DR, Schernthanner G, Hanefeld M, Brunetti P, the QUARTET Study Group: A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med. In press
28. Schernthaner G, Matthews D, Charbonnel B, Hanefeld M, Brunetti P: Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068-6076, 2004
29. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, the QUARTET Study Group: One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27:141-147, 2004
30. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti, Schernthaner G: Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomised, comparative study. Diabetes Metab Res Rev. In press
31. HDL). Clinical Biochem 34:583-588, 2001
32. Steel RGD, Torrie JH: Principles and procedures of statistics. New York, McGraw-Hill, 1960
33. Esposito K, Giugliano D, Nappo F, Marfella R, the Campanian Postprandial Hyperglycemia Study Group: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110:214-219, 2004
34. Wolever T, Chiasson J, Csima A, Hunt JA, Palmason C, Ross SA, Ryan EA: Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75-g oral glucose. Diabetes Care 21:336-340, 1998
35. Tan MH, Johns D, Glazer NB: Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 50:1113-1115, 2004
36. Heine RJ, Balkau B, Ceriello A, Del Prato S, Horton ES, Taskinen MR: What does postprandial hyperglycemia mean? Diabet Med 21:208-213, 2004
37. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486-494, 2003
38. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A: The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care 27:1647-1653, 2004